Navigation Links
World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester

Breakthrough in Research and Treatment of Rare but Devastating Condition

LONDON, June 1, 2007-Researchers at Queen Mary University London and the University of Leicester and have today (Friday June 1) announced a potential breakthrough in the treatment of a rare but devastating medical condition that can affect children and young people.

In a world first, the clinicians and scientists from the two universities have already treated one patient with promising results. Their preliminary data are published as a letter in the New England Journal of Medicine.

This is the first time research into a condition known as "idiopathic pulmonary haemosiderosis" has investigated the role of 'oxidative stress' and it is also the first time treatment has been carried out based on the research.

Queen Mary University London and the University of Leicester have combined world-class expertise in Child Health, Pulmonary Disease and Oxidative Stress research, plus access to patients with this rare disease. This combination of factors is unique to this collaboration.

Jonathan Grigg, Professor of Paediatric Respiratory and Environmental Medicine at Queen Mary University London, said: "Idiopathic pulmonary haemosiderosis is a rare disease, the cause of which is unknown.

"Affected patients have episodes of bleeding in the lungs, which often need hospital admissions, and in some cases it can be life threatening. This is normally combated by the use of continuous oral steroids (which can have major side effects).

"In a child local to Leicester, we were able to show, for the first time, that there was high levels of oxidative stress in the lungs. In addition, we treated the increased oxidative stress by using of an antioxidant, N-acetyl cysteine - which has no side effects. Since she has been on this treatment she has had no lung bleeds, and the steroid dose has been significantly reduced."

Dr Marcus Cooke, Senior lecturer in the Radiation and Oxidative Stress Section at the University of Leicester, added: "It is a really good feeling to be involved in a project looking at oxidative stress, that can make such an enormous difference to a person's quality of life.

"I think that we will see an increasing use of biomarkers of oxidative stress to support clinical decisions."

Dr Cooke said that idiopathic pulmonary haemosiderosis is a devastating condition. Characteristic of this condition is the accumulation of protein-bound iron in the lungs, a consequence of repeated bleeding in the lungs, coupled with inflammation and fibrosis. Ultimately this condition is usually fatal. Treatment to prevent the lung damage and prevent anaemia is a combination of corticosteroids and iron supplement.

Both chronic inflammation, and the presence of iron, released following bleeding into the lungs, can lead to a condition known as oxidative stress. Oxidative stress occurs when the production of free radicals, highly reactive chemicals, outweighs antioxidant defences. This leads to a great deal of damage to cells, and in particular DNA, the cell's 'blueprint', and is likely to be responsible for the fibrosis, as the lungs try to repair the damage done by free radicals.

"In order to establish whether oxidative stress was indeed associated with episodes of bleeding into the lungs, we measured a biomarker of oxidative stress, and a marker of damage to DNA specifically, in urine.

"We noted that levels of oxidative stress increased significantly following every bleed. With this in mind, and on the basis that antioxidants can potentially boost the body's natural defences, we began the patient on a course of the antioxidant drug N-acetyl cysteine. Five months into antioxidant therapy, the patient remains clinically well, and on a reduced dose of corticosteroids."

NOTE TO NEWSDESK: For more information, please contact:

Prof. Jona than Grigg Professor of Paediatric Respiratory and Environmental Medicine Institute of Cell and Molecular Science, Queen Mary University London Tel: 020 78822206

Dr Marcus Cooke, Radiation and Oxidative Stress Section Dept. Cancer Studies & Dept. Genetics University of Leicester Tel: 0116 2525825

ISSUED BY:

Ather Mirza Director of Press and Publications University of Leicester University Road Leicester LE1 7RH tel: 0116 252 3335 email: pressoffice@le.ac.uk Looking for an expert? Try http://www.le.ac.uk/press/experts/intro.html UNIVERSITY OF LEICESTER - A member of the 1994 Group of universities that share a commitment to research excellence, high quality teaching and an outstanding student experience. * England's top ranked University for teaching quality and overall satisfaction amongst universities teaching full time students - National Student Survey 2005 and 2006 * One of just 19 UK universities to feature in world's top 200- Shanghai Jiao Tong International Index, 2005 and 2006. Ranked as a Top 20 university by The Times Good University Guide. * Short listed Higher Education Institution of the Year - THES awards 2005 and 2006 * Students' Union of the Year award 2005, short listed 2006 Founded in 1921, the University of Leicester has 19,000 students from 120 countries. Teaching in 18 subject areas has been graded Excellent by the Quality Assurance Agency- including 14 successive scores - a consistent run of success matched by just one other UK University. Leicester is world renowned for the invention of DNA Fingerprinting by Professor Sir Alec Jeffreys and houses Europe's biggest academic Space Research Centre. 90% of staff are actively engaged in high quality research and 13 subject areas have been awarded the highest rating of 5* and 5 for research quality, demonstrating excellence at an international l evel. The University's research grant income places it among the top 20 UK research universities. The University employs over 3,000 people, has an annual turnover of ??.5m, covers an estate of 94 hectares and is engaged in a ??m investment programme- among the biggest of any UK university.

Ather Mirza Director of Press and Publications University of Leicester University Road Leicester LE1 7RH tel: 0116 252 3335 email: pressoffice@le.ac.uk Looking for an expert? Try http://www.le.ac.uk/press/experts/intro.html UNIVERSITY OF LEICESTER - A member of the 1994 Group of universities that share a commitment to research excellence, high quality teaching and an outstanding student experience. * England's top ranked University for teaching quality and overall satisfaction amongst universities teaching full time students - National Student Survey 2005 and 2006 * One of just 19 UK universities to feature in world's top 200- Shanghai Jiao Tong International Index, 2005 and 2006. Ranked as a Top 20 university by The Times Good University Guide. * Short listed Higher Education Institution of the Year - THES awards 2005 and 2006 * Students' Union of the Year award 2005, short listed 2006 Founded in 1921, the University of Leicester has 19,000 students from 120 countries. Teaching in 18 subject areas has been graded Excellent by the Quality Assurance Agency- including 14 successive scores - a consistent run of success matched by just one other UK University. Leicester is world renowned for the invention of DNA Fingerprinting by Professor Sir Alec Jeffreys and houses Europe's biggest academic Space Research Centre. 90% of staff are actively engaged in high quality research and 13 subject areas have been awarded the highest rating of 5* and 5 for research quality, demonstrating excellence at an international level. The University's research gran t income places it among the top 20 UK research universities. The University employs over 3,000 people, has an annual turnover of ??.5m, covers an estate of 94 hectares and is engaged in a ??m investment programme- among the biggest of any UK university.


'"/>




Related medicine technology :

1. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
2. MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2 Clinical Data at the World Asthma Meeting
3. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
4. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
5. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
6. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
7. Gentiums Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology
8. Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting
9. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
10. Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
11. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... REDWOOD CITY, Calif. , Feb. 9, 2016 /PRNewswire/ ... medical device company that is providing innovative evidence-based solutions ... it will release financial results for the fourth quarter ... Monday, February 29, 2016. Company management will host a ... p.m. Eastern Time) on Monday, February 29, 2016. ...
(Date:2/9/2016)... Feb. 9, 2016  Insulet Corporation (NASDAQ: PODD ) ... pump technology with its OmniPod ® ... has been appointed to Insulet,s Board of Directors. With ... eight of whom are independent. --> ... audit and finance experience and a deep knowledge of accounting, ...
(Date:2/9/2016)... 9, 2016 QGEN ... den Abschluss eines Kooperationsvertrags mit 10x Genomics ... in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology und ... Frankfurt Prime Standard: QIA) gab heute den ... die Entwicklung und Förderung umfassender Lösungen in ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ravages of ... (ALCA) to conduct a survey that takes a closer look at cases of TBI ... prevalence and causes of TBI among the aging population, and identifies the challenges associated ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience signed a ... network of laboratory service centers across the country. Launched in April of 2015, Apifiny ... detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... it has been awarded the prestigious Distinguished Emerald Club of the World award, ... by BoardRoom magazine, one of the most respected trade publications serving private clubs. ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... Workrite ... based company that has evolved from humble beginnings to being an internationally recognized leader ... company that we are today”, said Charlie Lawrence, President of Workrite. “Workrite recognized ...
(Date:2/10/2016)... FLA (PRWEB) , ... February 09, 2016 , ... ... team at Clevens Face and Body Specialists are delighted to welcome a new ... ARNP joins Clevens Face and Body Specialists as a nurse practitioner performing ...
Breaking Medicine News(10 mins):